| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Gamma 1 globin; Gamma 2 globin; Gamma A hemoglobin; Gamma globin; Hb F Agamma; Hb F Ggamma; HBG1; HBG2; HBGA; HBGR;;Hemoglobin gamma 1/2 |
| WB Predicted band size | Calculated MW: 16 kDa ; Observed MW: 12 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human Hemoglobin gamma 1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于HBG1/2抗体的3篇参考文献示例(文献信息为虚构模拟，仅供格式参考)：
---
1. **文献名称**：*Antibody-based detection of fetal hemoglobin in sickle cell disease*
**作者**：Smith A, et al.
**摘要**：本研究利用特异性HBG1/2抗体，通过免疫印迹和免疫组化技术，定量分析了镰状细胞贫血患者中胎儿血红蛋白(HbF)的表达水平，揭示了HbF升高与临床症状改善的相关性。
2. **文献名称**：*Developmental regulation of HBG1 and HBG2 in human erythropoiesis*
**作者**：Chen L, et al.
**摘要**：通过流式细胞术和免疫荧光技术，使用HBG1/2抗体追踪γ-珠蛋白在造血干细胞分化中的动态表达，证实了转录因子BCL11A对HBG1/2的抑制作用机制。
3. **文献名称**：*HBG1/2 antibodies enable isolation of fetal erythroid progenitors*
**作者**：Wang Y, et al.
**摘要**：开发了一种基于HBG1/2抗体的磁珠分选方法，成功分离出脐带血中的胎儿红系祖细胞，为研究血红蛋白转换障碍提供了新型实验工具。
---
如需真实文献，建议通过PubMed或Google Scholar检索关键词：
`"HBG1 antibody" OR "HBG2 antibody"` + `fetal hemoglobin`/`sickle cell`/`gene regulation`。
HBG1 and HBG2 (Hemoglobin Subunit Gamma 1 and 2) are fetal-specific globin genes encoding the γ-globin chains of fetal hemoglobin (HbF, α2γ2). Expressed predominantly during fetal development, HbF replaces embryonic hemoglobin by 8-10 weeks of gestation and is gradually supplanted by adult hemoglobin (HbA, α2β2) around birth. HBG1 and HBG2 differ by a single amino acid (glycine vs. alanine at position 136) due to gene duplication. Their expression is tightly regulated by transcription factors (e.g., BCL11A, ZBTB7A) and epigenetic modifiers, with silencing occurring postnatally in most individuals.
Antibodies targeting HBG1/2 are critical tools for studying hemoglobin switching mechanisms and disorders like β-hemoglobinopathies (e.g., sickle cell disease, β-thalassemia). Reactivating γ-globin expression to boost HbF levels is a therapeutic strategy for these conditions, as HbF inhibits pathogenic hemoglobin polymerization. HBG1/2 antibodies enable detection and quantification of γ-globin protein in research models (e.g., cell lines, transgenic mice) and clinical samples. They are widely used in techniques like Western blot, immunohistochemistry, and flow cytometry to assess HbF-inducing agents (e.g., hydroxyurea, CRISPR-editing therapies). Commercial HBG1/2 antibodies are typically raised against synthetic peptides or recombinant proteins, with validation required for species cross-reactivity and specificity due to high homology between HBG1 and HBG2. Recent studies also explore their diagnostic utility in monitoring HbF levels during gene therapy or drug trials.
×
